Maintaining therapeutic anticoagulation: The importance of keeping "within range"

Chest

Volumn 131, Issue 5, 2007, Pages 1277-1279

  Lane, Deirdre A ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; VITAMIN K GROUP;

ALCOHOL CONSUMPTION; ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; EDITORIAL; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER DYSFUNCTION; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM;

EID: 34248561915     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-0273     Document Type: Editorial

References (24)

1. Lip GYH, Edwards SJ. Stroke prevention with aspirin, warfarin, and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res 2006; 118:321-333
2. Albers GW. Atrial fibrillation and stroke: three new studies, three remaining questions. Arch Intern Med 1994; 154:1443-1448
3. Haustein KO. Pharmacokinetic and pharmocodynamic properties of oral anticoagulants, especially phenprocoumon. Semin Thromb Haemost 1999; 25:5-11
4. Lip GY, Boos CJ. Antithrombotic treatment in atrial fibrillation. Heart 2006; 92:155-161
5. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality. N Engl J Med 2003; 349:1019-1026
6. Levine MN, Raskob G, Beyth RJ, et al. Haemorrhagic complications of anticoagulant treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(Suppl 3):287S-310S
7. Petersen P, Grind M, Adler J, et al. Ximelagtran versus warfarin for stroke prevention in patients with non-valvular atrial fibrillation: SPORTIF II; A dose-guiding tolerability and safety study. J Am Coll Cardiol 2003; 41:1445-1451
8. van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: a systematic review and meta-regression. Chest 2006; 129:1155-1166
9. Jones M, McEwan P, Morgan CL, et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvular atrial fibrillation: a record linkage study in a large British population. Heart 2005; 91:472-477
10. van Walraven C, Oake N, Wells P, et al. Burden of potentially avoidable anticoagulant-associated hemorrhagic and thromboembolic events in the elderly. Chest 2007; 131:1508-1515
11. Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease- native and prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:457-482
12. Shireman TI, Howard PA, Kresowik TF, et al. Combined anticoagulant- antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 2004; 35:2362-2367
13. JBS-2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice prepared by British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. Heart 2005; 91(Suppl 5):v1-v52
14. National Institute for Health and Clinical Excellence. Atrial fibrillation: national clinical guideline for management in primary and secondary care. London, UK: Royal College of Physicians, 2006. Available at: www.nice.org.uk. Accessed February 12, 2007
15. Lip GYH, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest 2006; 130:1823-1827
16. Flaker GC, Gruber M, Connolly SJ, et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 2006; 152:967-973
17. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105:91-99
18. Kuijer PMM, Hutten BA, Prins MH, et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism Arch Intern Med 1999; 159:457-460
19. Shireman T, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006; 130:1390-1396
20. Lip GYH, Kamath S, Jafri M, et al. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation Project. Stroke 2002; 33:238-242
21. Khan TI, Kamali F, Kesteven P, et al. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol 2004; 126:557-564
22. Beyth RJ, Quinn L, Landefeld CS. A multi-component intervention to prevent major bleeding in older patients receiving warfarin: a randomised, controlled trial. Ann Intern Med 2000; 133:687-695
23. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006; 367:404-411
24. Witt DM, Sadler MA, Shanahan RL, et al. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005; 127:1515-1522